


LE-ATG-AS (SEQ ID NO: 1) uptake
(% of applied cpm)

FIG. 2



B





FIG. 3

LE-ATG-AS (SEQ ID NO: 1):



ATG-AS (SEQ ID NO: 1):






FIG. 4

A



B






FIG. 5

A




LE-ATG-ODN (SEQ ID NO: 1); (SEQ ID NO: 3) (10 μ M)




LE-ATG-AS (SEQ ID NO: 1) treatment time (h)

B




LE-ATG-ODN (SEQ ID NO: 1); (SEQ ID NO: 3) (8h)



LE-ATG-ODN (SEQ ID NO: 1); (SEQ ID NO: 3) concentration

FIG. 6






FIG. 7





FIG. 8






FIG. 9




FIG. 10

ANTISENSE *raf* AND TUMOR RADIOSENSITIZATION






FIG. 11

A LE-5132 (SEQ ID NO: 4):




B ISIS 5132 (SEQ ID NO: 4):



5' 15' 30' 1h 2h 4h 8h 24h 48h
Time after ODN injection


C

ODN concentration in plasma (µg/ml)



Time after ODN injection (h)

FIG. 12







FIG. 13

FIG. 14




FIG. 15






FIG. 17








FIG. 22

FIG. 23




FIG. 24




FIG. 25




FIG. 26A




FIG. 26B

